Simulation of Chemotherapy Effects in Older Breast Cancer Patients Who Have High Recurrence Scores

Journal of the National Cancer Institute,
30 Jun, 2020 ,

Young Chandle conducted a study to estimate chemotherapy effects by age and comorbidity level among women with early-stage, hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancers and Oncotype DX scores of 26 or higher. The researchers concluded that among women aged 65–89 years whose tumors indicate a high recurrence risk, only those aged 65–74 years with no or low or moderate comorbidity have small benefits from adding chemotherapy to endocrine therapy